Literature DB >> 35604445

Paraneoplastic musculoskeletal disorders: review and update for radiologists.

Kimia Khalatbari Kani1, Jack A Porrino2, Michael E Mulligan3, Felix S Chew4.   

Abstract

Rheumatic paraneoplastic syndromes are rare syndromes that occur at distant sites from the underlying tumor and may involve the bones, joints, fasciae, muscles, or vessels. In the absence of a known tumor, early recognition of a rheumatic syndrome as paraneoplastic permits dedicated work-up for, and potentially early treatment of an occult malignancy. Although there is a continuously growing list of paraneoplastic rheumatic disorders, not all of these disorders have a well-established association with a neoplastic process. The goals of this article are to review the clinical characteristics, diagnostic work-up, and imaging findings of well-documented rheumatic paraneoplastic disorders.
© 2022. The Author(s), under exclusive licence to International Skeletal Society (ISS).

Entities:  

Keywords:  Cancer-associated myositis; Hypertrophic osteoarthropathy; Palmar fasciitis and polyarthritis; Pancreatic panniculitis and polyarthritis; Paraneoplastic polyarthritis; Remitting seronegative symmetric synovitis with pitting edema; Rheumatic paraneoplastic syndromes; Tumor-induced osteomalacia

Year:  2022        PMID: 35604445     DOI: 10.1007/s00256-022-04074-w

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  67 in total

Review 1.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

Review 2.  Rheumatological manifestations of the leukaemias and graft versus host disease.

Authors:  J A Rennie; I A Auchterlonie
Journal:  Baillieres Clin Rheumatol       Date:  1991-08

Review 3.  Rheumatic paraneoplastic syndromes - A clinical link between malignancy and autoimmunity.

Authors:  Bernhard Manger; Georg Schett
Journal:  Clin Immunol       Date:  2017-07-21       Impact factor: 3.969

Review 4.  Tumor-Induced Osteomalacia.

Authors:  Pablo Florenzano; Iris R Hartley; Macarena Jimenez; Kelly Roszko; Rachel I Gafni; Michael T Collins
Journal:  Calcif Tissue Int       Date:  2020-06-05       Impact factor: 4.333

5.  Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment.

Authors:  Itsuro Endo; Seiji Fukumoto; Keiichi Ozono; Noriyuki Namba; Daisuke Inoue; Ryo Okazaki; Mika Yamauchi; Toshitsugu Sugimoto; Masanori Minagawa; Toshimi Michigami; Masaki Nagai; Toshio Matsumoto
Journal:  Endocr J       Date:  2015-07-01       Impact factor: 2.349

Review 6.  Phosphaturic mesenchymal tumors: A review and update.

Authors:  Andrew L Folpe
Journal:  Semin Diagn Pathol       Date:  2019-07-05       Impact factor: 3.464

7.  The diagnostic dilemma of tumor induced osteomalacia: a retrospective analysis of 144 cases.

Authors:  Juan Feng; Yan Jiang; Ou Wang; Mei Li; Xiaoping Xing; Li Huo; Fang Li; Wei Yu; Ding-Rong Zhong; Jin Jin; Yong Liu; Fang Qi; Wei Lv; Lian Zhou; Xun-Wu Meng; Wei-Bo Xia
Journal:  Endocr J       Date:  2017-05-26       Impact factor: 2.349

Review 8.  The Relationship Between Rheumatologic Disorders and Malignancies.

Authors:  Mandana Hashefi
Journal:  Rheum Dis Clin North Am       Date:  2018-06-13       Impact factor: 2.670

9.  Nonremission and Recurrent Tumor-Induced Osteomalacia: A Retrospective Study.

Authors:  Xiang Li; Yan Jiang; Li Huo; Huanwen Wu; Yong Liu; Jin Jin; Wei Yu; Wei Lv; Lian Zhou; Yu Xia; Ou Wang; Mei Li; Xiaoping Xing; Yue Chi; Ruizhi Jiajue; Lijia Cui; Xunwu Meng; Weibo Xia
Journal:  J Bone Miner Res       Date:  2019-11-15       Impact factor: 6.741

10.  FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting.

Authors:  Mara Riminucci; Michael T Collins; Neal S Fedarko; Natasha Cherman; Alessandro Corsi; Kenneth E White; Steven Waguespack; Anurag Gupta; Tamara Hannon; Michael J Econs; Paolo Bianco; Pamela Gehron Robey
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.